PLYX (Polaryx Therapeutics) Retained Earnings: $-102.18 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYX Polaryx Therapeutics Inc PLYX
13 GF Score
Price $2.26
View Full Analysis

What is Polaryx Therapeutics Retained Earnings?

Polaryx Therapeutics PLYX +2.73% 13 Retained Earnings is $-102.18 Mil as of Mar. 2026. GuruFocus rates PLYX with a GF Score™ of 13/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Polaryx Therapeutics's retained earnings for the quarter that ended in Mar. 2026 was $-102.18 Mil.

Polaryx Therapeutics's quarterly retained earnings declined from Sep. 2025 ($-98.14 Mil) to Dec. 2025 ($-99.64 Mil) and declined from Dec. 2025 ($-99.64 Mil) to Mar. 2026 ($-102.18 Mil).

Polaryx Therapeutics's annual retained earnings declined from Dec. 2023 ($-60.29 Mil) to Dec. 2024 ($-90.65 Mil) and declined from Dec. 2024 ($-90.65 Mil) to Dec. 2025 ($-99.64 Mil).

Polaryx Therapeutics  (NAS:PLYX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Polaryx Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Polaryx Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Polaryx Therapeutics Retained Earnings Chart

Polaryx Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Retained Earnings
-60.29 -90.65 -99.64

Polaryx Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only -95.70 -96.71 -98.14 -99.64 -102.18
PLYX
13GF Score
Polaryx Therapeutics Inc PLYX
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-102.18 Mil mean?
Polaryx Therapeutics (PLYX) has a Retained Earnings of $-102.18 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Polaryx Therapeutics and its competitors.
Is Polaryx Therapeutics' Retained Earnings too high?
Polaryx Therapeutics' current Retained Earnings is $-102.18 Mil. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' Retained Earnings compare to GUTS and NTHI?
Polaryx Therapeutics' Retained Earnings of $-102.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current Retained Earnings is $-102.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current Retained Earnings of $-102.18 Mil. The current Retained Earnings is $-102.18 Mil. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current Retained Earnings is $-102.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for PLYX

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price